Newscast – Page 147 – media

Like a baby– The vicious cycle of childhood obesity and snoring

Poor nutrition and lack of exercise lead to the increasing prevalence of obesity which, in turn, is the major predictor of diabetes and future risk of cardiovascular disease in western societies. v
- Source: medicalxpress
- 549
- November 20, 2017
cardiovascular disease diabetes obesity obstructive sleep apnea
Clinical trial shows treatment is ‘transformative’ for babies with spinal muscular atrophy

Infants with the most severe form of spinal muscular atrophy (SMA) were more likely to show gains in motor function and were 47 percent more likely to survive without permanent assisted ventilation support when treated with a new medication, according to a study published today in the New England Journal of Medicine. The drug, nusinersen, performed so well that the study was stopped early and the treatment was approved shortly thereafter by the U.S. Food and Drug Administration (FDA) for all patients with this progressive neuromuscular disorder.
- Source: sciencedaily
- 462
- November 17, 2017
Market Views neuromuscular disorder SMA
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation

Celgene Corporation and bluebird bio, Inc. announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple myeloma, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) eligibility by the European Medicines Agency (EMA).
- Source: ansa.it
- 597
- November 17, 2017
BTD CAR-T therapy Company Insight
Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II

Sangamo Therapeutics, Inc. (SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial ("the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing therapy for people with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
- Source: finance.yahoo
- 422
- November 17, 2017
Company Insight Hunter syndrome MPS II
Using social media big data to combat prescription drug crisis

Their study found that with proper research methods and attention to privacy and ethical issues, social media big data can reveal important information concerning drug abuse, such as user-reported side effects, drug cravings, emotional states, and risky behaviors.
- Source: drugdu
- 579
- November 17, 2017
prescription drug abuse
Jardiance is the first and only oral type 2 diabetes medicine approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.
- Source: finance.yahoo
- 613
- November 17, 2017
cardiovascular diabetes Jardiance® peripheral artery disease
How common are flu shot side effects?

With fall well underway and winter just around the corner, chances are your doctor, pharmacist, and maybe even your mom are telling you it's time to roll up your sleeve for a flu shot. If you're inclined to ignore them, we get it: No one really enjoys being jabbed with a needle.
- Source: foxnews
- 512
- November 17, 2017
flu shot
Medical first-Doctors attempt to gene-edit a living patient’s DNA

A man may soon be forever free of the previously incurable disease he was born with 44 years ago. On Monday, in a medical first, Brian Madeux received an experimental in-body gene-editing treatment intended to cure him of Mucopolysaccharidoses II, known as MPS II or Hunter syndrome, a rare disorder that causes progressive damage to the body's cells.
- Source: flipboard
- 437
- November 16, 2017
enzyme Hunter syndrome Market Views mucopolysaccharides
New dye gives scientists a clearer insight into the brain

Keele University researchers have designed a new dye that can be used to observe the electrical activity of neurons in the brain and could lead to finding a new and more efficient way of treating neurological diseases, as presented at the Society for Neuroscience annual conference in Washington, D.C. this week.
- Source: sciencedaily
- 419
- November 16, 2017
neurological Researches
Loxo Oncology Lands $1.55B Cancer Tie-Up With Bayer

Loxo Oncology struck a deal with Germany-based Bayer AG to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55 billion for the Connecticut-based company.
- Source: Biospace
- 852
- November 16, 2017
cancer larotrectinib Market Views therapy TRK

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.